MCL Literature Feed

This real-world study identifies key patient and systemic barriers limiting CAR-T therapy access for relapsed/refractory MCL, highlighting disparities between trial eligibility and clinical practice.

This large real-world study shows second primary malignancies in MCL patients double mortality risk versus non-MCL patients, mandating long-term surveillance for these subsequent cancers.

This review provides a treatment and sequencing algorithm for relapsed/refractory MCL, navigating the complex landscape of BTKi, BCL2i, CAR-T, bispecifics, and transplant for individualized patient care.

A distinct DNA demethylation signature in MCL tumors acts as a "fossil record" of early gene activation, offering a novel bioinformatic approach to understand the cancer's developmental origins.

This review summarizes how epigenetic dysregulation drives MCL pathogenesis, highlighting the potential for novel biomarkers and therapeutic targets based on mechanisms like DNA methylation and histone modification.

A new preclinical cell line and patient-derived xenograft model of a non-MCL lymphoma with a CCND1 rearrangement provides a tool to study the specific biological role of this key driver.

This longitudinal study reveals MCL acquires new high-risk genetic features after chemoimmunotherapy, explaining relapse and emphasizing the need for genomic profiling to guide subsequent therapies.

This case report details pleomorphic MCL presenting as life-threatening hemophagocytic lymphohistiocytosis (HLH), emphasizing the need for high clinical suspicion of this rare, sepsis-mimicking oncologic emergency.

This paper details a new UPLC-MS/MS method for rapid venetoclax plasma quantification, which could facilitate therapeutic drug monitoring to optimize dosing and toxicity management in MCL.

This case of MCL presenting as diffuse gastrointestinal polyposis mimicking hereditary syndromes underscores the need for histopathology to avoid misdiagnosis and ensure prompt immunochemotherapy for this rare presentation.

Undetectable MRD after induction chemotherapy identifies mantle cell lymphoma patients who may safely omit consolidative autologous stem cell transplant, enabling a personalized, de-escalation treatment strategy.

The CD19 CAR-T therapy relma-cel demonstrated high, durable responses (71% ORR, 18-month DOR) with manageable toxicity in heavily pretreated Chinese patients, establishing it as an effective option for relapsed/refractory MCL.

This phase 2 study of frontline acalabrutinib, lenalidomide, and anti-CD20 demonstrates high molecular response rates (67-90%) and 76% 4-year PFS, supporting a time-limited, MRD-driven, chemotherapy-free treatment strategy.

This large retrospective study shows rituximab maintenance after first-line bendamustine-rituximab significantly improves both event-free and overall survival, supporting its use as a standard of care.

In a retrospective ZUMA-2 analysis, prior ibrutinib exposure, versus acalabrutinib, improved brexu-cel CAR-T efficacy and PFS by inducing a more favorable cytotoxic T-cell phenotype.

This US real-world study describes treatment patterns and outcomes for covalent BTK inhibitors in relapsed/refractory MCL, providing crucial benchmarks for routine clinical practice outside of trial settings.

This case report describes follicular lymphoma of the larynx and is not relevant to mantle cell lymphoma research or clinical practice.

This case report identifies fingertip fissures as a rare dermatologic toxicity of ibrutinib in an elderly MCL patient, expanding the known adverse event profile for this common therapy.

The HSP90-MYC-CDK9 molecular network is identified as a key driver of therapeutic resistance in MCL, suggesting HSP90 or CDK9 inhibitors as potential strategies to overcome it.

This report summarizes the 2025 LRF MCL Workshop, highlighting key research developments in pathogenesis, resistance, and novel therapies, thereby setting the agenda for future clinical and translational research.

High expression of the lncRNA MALAT1 is a novel, independent biomarker for favorable prognosis in MCL, inversely correlating with proliferation signatures and EZH2 activity.

Population-level data confirms rituximab maintenance improves overall survival after R-CHOP induction, with a notable benefit for patients achieving only a partial response.

This retrospective study found one case of occult mantle cell lymphoma in 1328 adult tonsillectomies for benign indications, underscoring the value of routine histopathology for unexpected diagnoses.

This real-world study shows bendamustine-rituximab is the most common frontline therapy and BTK inhibitors for second-line, but median overall survival plummets in later lines, highlighting significant unmet need.

This review positions CAR-T and bispecific antibodies as complementary tools for relapsed/refractory MCL, advocating for individualized sequencing and combinations to optimize outcomes in heavily pretreated, high-risk patients.

The combination of acalabrutinib with bendamustine-rituximab is evaluated as a frontline therapy for elderly MCL patients, aiming to improve outcomes over standard chemoimmunotherapy.

A novel fluorescence-based assay quantifies pirtobrutinib in biological fluids, potentially enabling therapeutic drug monitoring to optimize dosing, manage toxicity, and study resistance in MCL patients.

This meta-analysis quantifies the high incidence of neurotoxicity (ICANS) with brexucabtagene autoleucel in MCL, finding 61% of patients experience any grade and 33% experience severe events.

This case report describes the rare co-occurrence of MCL and CLL/SLL, highlighting the diagnostic and therapeutic challenges that require careful pathologic evaluation to guide appropriate treatment.

This Chinese real-world study confirms autologous transplant consolidation improves survival in young, fit, lower-risk MCL, with added benefit from post-transplant maintenance using novel agents.